Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. on September 19, 2013. The report discloses corporate governance actions regarding the appointment of certain officers and the granting of compensatory stock options. Note: The request metadata references "Sonoma Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Oculus Innovative Sciences, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on non-financial corporate events related to executive compensation.
Material Changes
The material change reported is the approval of stock option awards by the Compensation Committee on September 19, 2013. These grants were made pursuant to the Company's stock incentive plans and the 2013 Bonus Plan.
- Board of Directors: Messrs. Jay Birnbaum, Richard Conley, and Greg French were each granted 8,027 options. Mr. Jerry McLaughlin was granted 5,351 options (prorated for service less than one year).
- Executive Officers: Robert Miller (CFO) was granted 26,756 options in lieu of cash under the 2013 Bonus Plan. Sameer Harish (CFO of subsidiary Ruthigen, Inc.) was granted 5,351 options in lieu of cash.
- Terms: All options were issued at an exercise price equal to the closing stock price on the grant date and vest quarterly over a three-year schedule.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items beyond the specific compensation grants detailed above.
Investor Verification Checklist
- Verify the total number of options granted (48,462 total) and the specific exercise price based on the September 19, 2013 closing stock price.
- Confirm the impact of these grants on the company's diluted share count and potential dilution to existing shareholders.
- Review the Company's 2013 Bonus Plan and stock incentive plans to understand the full scope of compensation structures.
- Clarify the discrepancy between the request metadata (Sonoma Pharmaceuticals) and the filing registrant (Oculus Innovative Sciences).